Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment

Supportive Care in Cancer

Volumn 24, Issue 11, 2016, Pages 4779-4789

  Zanville, Noah R ^a,b   Nudelman, Kelly N H ^a,b,c   Smith, Dori J ^c   Von Ah, Diane ^a   McDonald, Brenna C ^c,d   Champion, Victoria L ^a,b,d   Saykin, Andrew J ^a,c,d  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; CIPN; Perceived occupational function; Peripheral neuropathy; Survivorship; Symptoms; Work

Indexed keywords

AROMATASE INHIBITOR; CARBOPLATIN; DOCETAXEL; PACLITAXEL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVOR; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; EMPLOYMENT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MEDICAL RECORD; MUSCLE CRAMP; MUSCLE WEAKNESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REGRESSION ANALYSIS; VALIDATION STUDY; WELLBEING; WORK CAPACITY; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; PATHOLOGY; PROCEDURES; QUESTIONNAIRE; SUBACUTE CARE; SURVIVOR; TRENDS;

BREAST NEOPLASMS; EMPLOYMENT; FEMALE; HUMANS; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; SUBACUTE CARE; SURVEYS AND QUESTIONNAIRES; SURVIVORS;

EID: 84979995855     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-016-3329-5     Document Type: Article

References (42)

1. Islam T et al. (2014) Factors associated with return to work of breast cancer survivors: a systematic review. BMC Public Health 14(Suppl 3):S8
2. Spelten ER, Sprangers MA, Verbeek JH (2002) Factors reported to influence the return to work of cancer survivors: a literature review. Psychooncology 11(2):124–131
3. Tamminga SJ et al. (2012) Breast cancer survivors’ views of factors that influence the return-to-work process—a qualitative study. Scand J Work Environ Health 38(2):144–154
4. Ahn E et al. (2009) Impact of breast cancer diagnosis and treatment on work-related life and factors affecting them. Breast Cancer Res Treat 116(3):609–616
5. Banning M (2011) Employment and breast cancer: a meta-ethnography. Eur J Cancer Care (Engl) 20(6):708–719
6. Bradley CJ et al. (2005) Short-term effects of breast cancer on labor market attachment: results from a longitudinal study. J Health Econ 24(1):137–160
7. Mahon, S.M., et al. (2011) Breast cancer, in Site specific series, S.M. Mohan, Editor. Oncology Nursing Society. 248
8. de Boer, A.G., et al. (2011) Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev (2): p. CD007569
9. Wolf SL et al. (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20(3):625–632
10. Hershman DL et al. (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967
11. Mols, F., et al. (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer
12. Driessen CM et al. (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881
13. Sorbe B et al. (2012) A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 40(3):773–781
14. Bhatnagar B et al. (2014) Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus 3:366
15. Speck RM et al. (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):e234–e240
16. Dougherty PM et al. (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142
17. Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28
18. United States Department of Labor (2016) Labor force by sex, 2014 and projected 2022. [cited 2016 April 25]; Available from: http://www.dol.gov/wb/stats/laborforce_sex_projected_2014_2022_txt.htm
19. American Cancer Society (2016) Facts and figures, A.C. Society, Editor. Atlanta
20. Bradley CJ et al. (2007) Employment and cancer: findings from a longitudinal study of breast and prostate cancer survivors. Cancer Investig 25(1):47–54
21. Chirikos TN, Russell-Jacobs A, Jacobsen PB (2002) Functional impairment and the economic consequences of female breast cancer. Women Health 36(1):1–20
22. Forsyth PA et al. (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neuro-Oncol 35(1):47–53
23. Park, S.B., et al. (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin
24. Osmani K et al. (2012) Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol 259(9):1936–1943
25. Pignata S et al. (2006) Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in ovarian cancer (MITO-4) retrospective study. BMC Cancer 6:5
26. Hershman DL et al. (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774
27. Smith, E.M., et al. (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, in JAMA. United States. 1359–67
28. Tanay, M.A., J. Armes, and E. Ream (2016) The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care (Engl)
29. Pike CT et al. (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848
30. Nudelman KN et al. (2014) Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One 9(5):e96713
31. Nudelman KN et al. (2016) Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol 34(7):677–683
32. McDonald BC et al. (2013) Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 30(Suppl):S117–S125
33. Smith, E.M. (2013) Current methods for the assessment and management of taxane-related neuropathy, in Clin J Oncol Nurs. United States. 22–34
34. Huang HQ et al. (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17(2):387–393
35. Griffith KA et al. (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15(4):314–325
36. Beijers A et al. (2014) Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. J Community Support Oncol 12(11):401–406
37. Park SB et al. (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16(5):708–716
38. Calhoun EA et al. (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748
39. Kuroi K et al. (2009) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 17(8):1071–1080
40. Argyriou AA et al. (2005) Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 252(12):1459–1464
41. Bakitas, M.A. (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy, in Nurs Res. United States. 323–31
42. Marineo G et al. (2012) Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag 43(1):87–95